Install
Biotech
Biotechnology, gene editing, biopharma platforms, and clinical pipelines.
- 9 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
- Aerospace
- Agriculture
- Banking (Industry)
- Computing
- Consumer Goods
- Defense
- Energy & Utilities
- Entertainment
- Food & Beverage
- Government
- Healthcare
- Real Estate (Commercial)
- Management & Consulting
- Manufacturing
- Technology
- Telecom
- Transportation & Logistics
- Automotive
- Construction
- Education & EdTech
- Hospitality & Travel
- Insurance (Industry)
- Mining & Materials
- Pharmaceuticals
Latest in Biotech
Sarcomatrix Therapeutics Provides Update on Board Expansion and Rare Disease Programs
5+ hour, 53+ min ago (265+ words) Reno, NV, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Sarcomatrix Therapeutics Corporation, a preclinical-stage biopharmaceutical company developing therapies for rare neuromuscular disease, today provided a business update covering its two development programs, its expanded board of directors, and the external partners now engaged across…...
NVCT: Lead assets show strong efficacy in PNH and IgAN, with pivotal data and expansion plans ahead
4+ hour, 36+ min ago (82+ words) TradingView A recent in-licensing deal brought two promising compounds, including a once-daily oral factor B inhibitor with strong efficacy in PNH and IgAN, and a second-generation BRAF inhibitor for oncology. Robust funding supports clinical progress, with pivotal studies and key…...
JNJ: Accelerated growth, pipeline innovation, and MedTech advances support double-digit targets
5+ hour, 56+ min ago (64+ words) TradingView The event highlighted a focused portfolio driving accelerated growth, robust pipeline progress, and strategic capital allocation. Advanced therapies in oncology and immunology, new product launches, and MedTech innovation underpin double-digit growth targets through the decade. Based on Johnson & Johnson…...
EU-backed investment fuels nasal spray trials for viral lung treatments
4+ hour, 50+ min ago (13+ words) The Brussels Times...
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
2+ hour, 54+ min ago (267+ words) Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to initiate in first quarter of 2027 46% workforce reduction and other cost-saving…...
Quaker Houghton to launch EMDUR™ Biotechnology at Aluminium Düsseldorf 2026
11+ hour, 41+ min ago (455+ words) This image has been obtained via official Press Release Quaker Houghton (NYSE: KWR), the global leader in industrial process fluids, will exhibit at Aluminium Düsseldorf 2026 (6–8 October), where it will introduce its EMDUR™ biotechnology alongside a portfolio of rolling fluids, maintenance…...
Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery - AOL
1+ hour, 55+ min ago (184+ words) AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it has signed an agreement for a research collaboration led by Alice Stanton, PhD from Massachusetts General Hospital (MGH)…...
Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery | National Business | joplinglobe.com
1+ hour, 55+ min ago (186+ words) Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery The Joplin Globe - Download the Globe app to my phone or tablet Aptar and Massachusetts General Hospital Collaborate on Platform to…...
Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery
1+ hour, 55+ min ago (231+ words) Eagle-Tribune Aptar and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Sep 14, 2026-- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer…...
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029
3+ hour, 25+ min ago (257+ words) Labcorp Holdings on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day. The health care company emphasized its innovation roadmap, technological advancements and solid financial expectations for the coming years. The company validated its full-year…...